Investee Company – Coley Pharmaceutical Group
Investee Company Country – US/Germany
Investee Company Business Type – Drug Discovery
Type of Financing – Expansion – second funding round
Equity Providers – DWS Investment, DVG (advised by AP Asset Management), Commerzbank Private Equity, Bayview 2000, Global Life Science Partners, Techno Venture Management, QIAGEN, Alpinvest Holding (NIB Capital), Alafi Capital.
Equity Leader (Individual) – None Named.
Debt Providers – No debt financing.
Debt Type – N/A
Debt Leader (Individual) – N/A
Equity Amount – $60 million
Total Deal Value – $60 million
Other Advisors – AP Asset Management
Comments – Since the first round of financing in August 1999 Coley has expanded its management team, and improved its research capabilities. The first round of financing for $12.9million was led by TVM Techno Venture Management of Munich, Germany, as well as Alafi Capital Co., QIAGEN NV, Alpinvest Holding NV, Kredietbank S.A. Luxembourgeoise, and Mulligan Beteiligungs GmbH. As a result of the latest financing round Andreas Bremer, managing director of AP Asset Managment, has joined the board of directors at Coley.